Enhancing inpatient chemo/immunotherapy stewardship: A novel scoring rubric approach to optimize utilization and reduce costs. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results